Foghorn Therapeutics Inc.
HealthcareNASDAQ:FHTX · NASDAQ Global Market
+$0.12 today
Vol 0.16M · Avg 0.16M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
68.5%
avg -12107.0%
ROIC
-58.9%
avg -79.3%
ROA
-37.5%
avg -58.2%
Analysis
ROE is currently the strongest return metric at 68.5% versus its period average of -12107.0%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Adrian H. Gottschalk | President, Chief Executive Officer & Director | $1.03M | — | 50 | $240,792.00 | 0.41% |
Steven F. Bellon | Chief Scientific Officer | $730,200.00 | — | 61 | $300,000.00 | 0.51% |
Alfonso Quintas Cardama | Chief Medical Officer | $714,360.00 | — | 55 | $300,000.00 | 0.51% |
Ryan D. Maynard | Chief Financial Officer | $637,806.00 | — | 57 | $0.00 | <0.01% |
Michael J. LaCascia | Chief Legal Officer | $565,500.00 | — | 61 | $295,000.00 | 0.50% |
Anna Rivkin | Chief Business Officer | $348,672.00 | — | 51 | $165,000.00 | 0.28% |
Saurabh Sewak | Vice President of Corporate Development | — | — | — | — | — |
Karin Hellsvik | Chief of Staff to the CEO, VP, Head of Corporate Affairs, Investor Relations & Operations | — | — | — | — | — |
Carlos Costa | Chief People Officer | — | — | 53 | $230,000.00 | 0.39% |
Gerald R. Crabtree | Founder & Member of Scientific Advisory Board | — | — | — | — | — |
Michael Garcia-Webb | VP, Program Executive & Chief of Staff Research | — | — | — | $295,000.00 | 0.50% |
Jeffrey Sacher | Treasurer | — | — | 60 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | +32.3% (8yr)7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Forward estimates point to Revenue at +32.3% (8yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Assembly Biosciences, Inc.
NASDAQ:ASMB
$364.90M
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
$353.00M
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
$276.28M
Entrada Therapeutics, Inc.
NASDAQ:TRDA
$250.78M
Zura Bio Limited
NASDAQ:ZURA
$240.58M
Sagimet Biosciences Inc.
NASDAQ:SGMT
$211.13M
Arcturus Therapeutics Holdings Inc.
NASDAQ:ARCT
$198.11M
Humacyte, Inc.
NASDAQ:HUMA
$177.24M
Immuneering Corporation
NASDAQ:IMRX
$152.11M
Pyxis Oncology, Inc.
NASDAQ:PYXS
$111.51M
Who manages FHTX?
Foghorn Therapeutics Inc. (FHTX) lists 12 active executives. The top listed executive is Adrian H. Gottschalk, President, Chief Executive Officer & Director.
Are FHTX insiders buying or selling?
Recent insider activity shows net buying of $37.84T.
Explore More
Continue the stock analysis
Jump to another research area for this company.